(5R)-5-(azidomethyl)-3-(3-fluoro-2-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (5R)-5-(azidomethyl)-3-(3-fluoro-2-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
• 化学式: C14H16FN5O3
• 分子量: 321.31
• InChiKey: VTVRXBKFKIAZBG-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56.4
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Process For Preparation Of Linezolid
  申请人：Mankind Research Centre

  公开号：US20170217911A1

  公开（公告）日：2017-08-03

  The present invention relates to an improved process for the preparation of Linezolid of Formula-I comprising reacting compound of Formula-II with compound of Formula-III in presence of metal base wherein, said metal base is prepared in situ in a single lot. The invention also relates to an isolated acetamide impurity of Formula-IV produced in the process for preparation of Linezolid, its purification and its use as a reference marker.

  本发明涉及一种改进的制备Formula-I的利奈唑胺的方法，包括在金属碱存在下，将Formula-II的化合物与Formula-III的化合物反应，其中所述金属碱在一个批次中原位制备。该发明还涉及在利奈唑胺制备过程中产生的Formula-IV的孤立乙酰胺杂质，以及其纯化和用作参考标记的用途。
• Solid forms of linezolid and processes for preparation thereof
  申请人：Aronhime Judith

  公开号：US20060111350A1

  公开（公告）日：2006-05-25

  Novel crystalline forms of Linezolid, designated as Form TIII, Form V, Form VI, Form IX, Form X, Form XII, Form XIV, Form XVII, and Form XVIII, are disclosed. The novel crystalline forms are characterized by powder X-ray diffraction, FTIR and FTRaman spectroscopy, and differential scanning calorimetry. Methods of preparing the novel crystalline forms, pharmaceutical compositions comprising the novel crystalline forms, and methods of using the novel crystalline forms to treat gram positive bacterial infections are also described. Amorphous Linezolid is also disclosed.

  本文披露了Linezolid的新晶体形式，包括TIII型、V型、VI型、IX型、X型、XII型、XIV型、XVII型和XVIII型。这些新晶体形式的特征是通过粉末X射线衍射、傅里叶变换红外光谱和傅里叶变换拉曼光谱以及差示扫描量热法进行表征。本文还描述了制备这些新晶体形式的方法、包含这些新晶体形式的制药组合物以及使用这些新晶体形式治疗革兰氏阳性细菌感染的方法。此外，本文还披露了非晶态Linezolid。
• Isolated bis-linezolid, preparation thereof, and its use as a reference standard
  申请人：Nidam Tamar

  公开号：US20060252932A1

  公开（公告）日：2006-11-09

  The present invention provides an isolated linezolid (1) impurity, bis-linezolid (4), preparation thereof and its use as a reference standard.

  本发明提供了一种孤立的利奈唑胺（1）杂质，双利奈唑胺（4），其制备方法以及其作为参考标准的用途。
• SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF
  申请人：Teva Pharmaceutical Industries Ltd

  公开号：EP1745028A2

  公开（公告）日：2007-01-24
• PROCESSES FOR THE PREPARATION OF LINEZOLID INTERMEDIATE
  申请人：Teva Pharmaceutical Industries Ltd

  公开号：EP1866295A2

  公开（公告）日：2007-12-19